Published in J Pharmacol Exp Ther on November 03, 2004
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A (2007) 3.09
Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest (2007) 2.78
Sheddable coatings for long-circulating nanoparticles. Pharm Res (2007) 2.15
Nonviral methods for siRNA delivery. Mol Pharm (2009) 1.50
Liposomes as nanomedical devices. Int J Nanomedicine (2015) 1.29
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci (2011) 1.24
Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther (2011) 1.23
Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Adv Drug Deliv Rev (2012) 1.18
Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles. Mol Ther Nucleic Acids (2013) 1.05
Role of the methoxy group in immune responses to mPEG-protein conjugates. Bioconjug Chem (2012) 1.02
Stealth filaments: Polymer chain length and conformation affect the in vivo fate of PEGylated potato virus X. Acta Biomater (2015) 0.90
Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.88
Designer lipids for drug delivery: from heads to tails. J Control Release (2014) 0.88
Low molecular weight chitosan nanoparticulate system at low N:P ratio for nontoxic polynucleotide delivery. Int J Nanomedicine (2012) 0.87
Advances in Lipid Nanoparticles for siRNA Delivery. Pharmaceutics (2013) 0.85
Effects of a novel pH-sensitive liposome with cleavable esterase-catalyzed and pH-responsive double smart mPEG lipid derivative on ABC phenomenon. Int J Nanomedicine (2011) 0.85
Optimizing Druggability through Liposomal Formulations: New Approaches to an Old Concept. ISRN Pharm (2012) 0.84
Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus. Acta Biomater (2016) 0.79
Virus-based nanomaterials as positron emission tomography and magnetic resonance contrast agents: from technology development to translational medicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.79
Virus-Based Nanoparticles as Versatile Nanomachines. Annu Rev Virol (2015) 0.78
Zwitterionic poly(carboxybetaine)-based cationic liposomes for effective delivery of small interfering RNA therapeutics without accelerated blood clearance phenomenon. Theranostics (2015) 0.78
DNA nanocarriers for systemic administration: characterization and in vivo bioimaging in healthy mice. Mol Ther Nucleic Acids (2013) 0.76
Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future. Toxicol Appl Pharmacol (2016) 0.76
Quantitative modeling of the high-throughput production and in vivo kinetics of (drug-encapsulating) liposomes. PLoS One (2010) 0.75
RNAi therapy to the wall of arteries and veins: anatomical, physiologic, and pharmacological considerations. J Transl Med (2017) 0.75
Rational design of cationic lipids for siRNA delivery. Nat Biotechnol (2010) 4.97
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther (2010) 3.26
Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther (2006) 2.40
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl (2012) 1.87
Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates. J Med Chem (2008) 1.28
Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther (2011) 1.23
Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther (2013) 1.11
Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev (2002) 1.09
Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol Cancer Ther (2009) 1.07
Systemic activation of glutamate dehydrogenase increases renal ammoniagenesis: implications for the hyperinsulinism/hyperammonemia syndrome. Am J Physiol Endocrinol Metab (2010) 1.06
Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta (2006) 1.04
Extrusion technique to generate liposomes of defined size. Methods Enzymol (2003) 1.03
Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res (2010) 1.03
Excitatory amino acids in rostral ventrolateral medulla support blood pressure during water deprivation in rats. Am J Physiol Heart Circ Physiol (2004) 0.97
Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core. J Phys Chem C Nanomater Interfaces (2012) 0.93
Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci (2005) 0.92
Effects of block copolymer properties on nanocarrier protection from in vivo clearance. J Control Release (2012) 0.92
Identification and validation of differentially expressed transcripts in a hepatocyte model of cold-induced glycerol production in rainbow smelt (Osmerus mordax). Am J Physiol Regul Integr Comp Physiol (2011) 0.86
In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res (2004) 0.84
Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts. Leuk Lymphoma (2010) 0.81
Glycerol production in rainbow smelt (Osmerus mordax) may be triggered by low temperature alone and is associated with the activation of glycerol-3-phosphate dehydrogenase and glycerol-3-phosphatase. J Exp Biol (2006) 0.80
Micelles as intermediates in the preparation of protein-liposome conjugates. Bioconjug Chem (2006) 0.79
Transcript levels of class I GLUTs within individual tissues and the direct relationship between GLUT1 expression and glucose metabolism in Atlantic cod (Gadus morhua). J Comp Physiol B (2014) 0.78
The combination of stabilized plasmid lipid particles and lipid nanoparticle encapsulated CpG containing oligodeoxynucleotides as a systemic genetic vaccine. J Gene Med (2009) 0.78
The effect of bilayer and hexagonal H(II) phase lipid films on transepidermal water loss. Exp Dermatol (2006) 0.78
Glucose uptake and metabolism by red blood cells from fish with different extracellular glucose levels. J Exp Biol (2012) 0.76
Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp Hematol (2011) 0.76
Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2014) 0.76
Pregnancy and acute baroreflex resetting in conscious rabbits. Am J Physiol Regul Integr Comp Physiol (2002) 0.75
Osmotic pressure-adaptive responses in the eye tissues of rainbow smelt (Osmerus mordax). Mol Vis (2011) 0.75
Methods for the preparation of protein-oligonucleotide-lipid constructs. Bioconjug Chem (2006) 0.75